Mechanisms of cardiovascular protection of non-insulin antidiabetic medications

Patients with type 2 diabetes mellitus die most frequently from cardiovascular disease (CVD). Metabolic control is a cornerstone of both primary and secondary prevention of CVD: its important is two-fold since the normalization of HbA1c not only counteracts the onset, and the progression of microvas...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Angelo Avogaro
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2018
Materias:	cardiovascular disease type 2 diabetes mellitus complications of diabetes mellitus dipeptidyl peptidase iv inhibitors glucagon-like peptide 1 sodium glucose transporter 2 Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/7aa9954a25364fdab808bcab645aff1a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7aa9954a25364fdab808bcab645aff1a
record_format	dspace
spelling	oai:doaj.org-article:7aa9954a25364fdab808bcab645aff1a2021-11-14T09:00:21ZMechanisms of cardiovascular protection of non-insulin antidiabetic medications2072-03512072-037810.14341/DM9816https://doaj.org/article/7aa9954a25364fdab808bcab645aff1a2018-11-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/9816https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Patients with type 2 diabetes mellitus die most frequently from cardiovascular disease (CVD). Metabolic control is a cornerstone of both primary and secondary prevention of CVD: its important is two-fold since the normalization of HbA1c not only counteracts the onset, and the progression of microvascular complication, but has also important and positive role in reducing the risk of major adverse cardiovascular events (MACE). However, among the available glucose-lowering medications, some exert a direct CV protection independently from their ability to normalize metabolic control. In this review I will highlight the pathophysiological mechanisms underlying the claimed cardiovascular protection of the different glucose-lowering drugs, the available evidence-based data for their protection, the potential adverse effects, and the different phenotypes of patients eligible for a specific treatment. The knowledge of pathophysiological mechanisms for CV protection of each glucose-lowering medication, and the constraints of their use supports the health care professionals to individualize the normalization of metabolic control in patients with type 2 diabetes mellitus.Angelo AvogaroEndocrinology Research Centrearticlecardiovascular diseasetype 2 diabetes mellituscomplications of diabetes mellitusdipeptidyl peptidase iv inhibitorsglucagon-like peptide 1sodium glucose transporter 2Nutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 21, Iss 5, Pp 376-385 (2018)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	cardiovascular disease type 2 diabetes mellitus complications of diabetes mellitus dipeptidyl peptidase iv inhibitors glucagon-like peptide 1 sodium glucose transporter 2 Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	cardiovascular disease type 2 diabetes mellitus complications of diabetes mellitus dipeptidyl peptidase iv inhibitors glucagon-like peptide 1 sodium glucose transporter 2 Nutritional diseases. Deficiency diseases RC620-627 Angelo Avogaro Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
description	Patients with type 2 diabetes mellitus die most frequently from cardiovascular disease (CVD). Metabolic control is a cornerstone of both primary and secondary prevention of CVD: its important is two-fold since the normalization of HbA1c not only counteracts the onset, and the progression of microvascular complication, but has also important and positive role in reducing the risk of major adverse cardiovascular events (MACE). However, among the available glucose-lowering medications, some exert a direct CV protection independently from their ability to normalize metabolic control. In this review I will highlight the pathophysiological mechanisms underlying the claimed cardiovascular protection of the different glucose-lowering drugs, the available evidence-based data for their protection, the potential adverse effects, and the different phenotypes of patients eligible for a specific treatment. The knowledge of pathophysiological mechanisms for CV protection of each glucose-lowering medication, and the constraints of their use supports the health care professionals to individualize the normalization of metabolic control in patients with type 2 diabetes mellitus.
format	article
author	Angelo Avogaro
author_facet	Angelo Avogaro
author_sort	Angelo Avogaro
title	Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
title_short	Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
title_full	Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
title_fullStr	Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
title_full_unstemmed	Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
title_sort	mechanisms of cardiovascular protection of non-insulin antidiabetic medications
publisher	Endocrinology Research Centre
publishDate	2018
url	https://doaj.org/article/7aa9954a25364fdab808bcab645aff1a
work_keys_str_mv	AT angeloavogaro mechanismsofcardiovascularprotectionofnoninsulinantidiabeticmedications
_version_	1718429540597891072

Mechanisms of cardiovascular protection of non-insulin antidiabetic medications

Ejemplares similares